You just read:

Lilly's CYRAMZA® (ramucirumab) Becomes First FDA-Approved Biomarker-Driven Therapy in Patients with Hepatocellular Carcinoma

News provided by

Eli Lilly and Company

May 13, 2019, 06:45 ET